Research ArticleArticle
The cannabinoid CB2 agonist AM1710 differentially suppresses distinct pathological pain states and attenuates morphine tolerance and withdrawal
Ai-Ling Li, Xiaoyan Lin, Amey S Dhopeshwarkar, Ana Carla Thomaz, Lawrence M Carey, Yingpeng Liu, Spyros P Nikas, Alexandros Makriyannis, Ken Mackie and Andrea G Hohmann
Molecular Pharmacology November 30, 2018, mol.118.113233; DOI: https://doi.org/10.1124/mol.118.113233
Ai-Ling Li
1 Indiana University;
Xiaoyan Lin
1 Indiana University;
Amey S Dhopeshwarkar
1 Indiana University;
Ana Carla Thomaz
1 Indiana University;
Lawrence M Carey
1 Indiana University;
Yingpeng Liu
2 Northeastern University
Spyros P Nikas
2 Northeastern University
Alexandros Makriyannis
2 Northeastern University
Ken Mackie
1 Indiana University;
Andrea G Hohmann
1 Indiana University;
Jump to comment:
No eLetters have been published for this article.
In this issue
Research ArticleArticle
The cannabinoid CB2 agonist AM1710 differentially suppresses distinct pathological pain states and attenuates morphine tolerance and withdrawal
Ai-Ling Li, Xiaoyan Lin, Amey S Dhopeshwarkar, Ana Carla Thomaz, Lawrence M Carey, Yingpeng Liu, Spyros P Nikas, Alexandros Makriyannis, Ken Mackie and Andrea G Hohmann
Molecular Pharmacology November 30, 2018, mol.118.113233; DOI: https://doi.org/10.1124/mol.118.113233
Research ArticleArticle
The cannabinoid CB2 agonist AM1710 differentially suppresses distinct pathological pain states and attenuates morphine tolerance and withdrawal
Ai-Ling Li, Xiaoyan Lin, Amey S Dhopeshwarkar, Ana Carla Thomaz, Lawrence M Carey, Yingpeng Liu, Spyros P Nikas, Alexandros Makriyannis, Ken Mackie and Andrea G Hohmann
Molecular Pharmacology November 30, 2018, mol.118.113233; DOI: https://doi.org/10.1124/mol.118.113233
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement